A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma

A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma.

Hamilton AK, Radaoui AB, Tsang M, Martinez D, Conkrite KL, Patel K, Sidoli S, Delaidelli A, Modi A, Rokita JL, Lane MV, Hartnett N, Lopez RD, Zhang B, Zhong C, Ennis B, Miller DP, Brown MA, Rathi KS, Raman P, Pogoriler J, Bhatti T, Pawel B, Glisovic-Aplenc T, Teicher B, Erickson SW, Earley EJ, Bosse KR, Sorensen PH, Krytska K, Mosse YP, Havenith KE, Zammarchi F, van Berkel PH, Smith MA, Garcia BA, Maris JM, Diskin SJ.Cancer Cell. 2024 Oct 23:S1535-6108(24)00366-0. doi: 10.1016/j.ccell.2024.10.003. Online ahead of print.PMID: 39454577
[PDF] [DOI]